Open an account

ANI Pharmaceuticals

ANIP · NASDAQ

$72.67+$0.11 (+0.15%)TodayMarket closed ·
Prev close $72.56

About ANIP

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

Employees
970
Headquarters
Baudette, Minnesota
Listed
May 4, 2000
Sector
Health Care
Industry
Pharmaceuticals
Website
anipharmaceuticals.com

ANIP key statistics

Market cap
1.67B
Price-earnings ratio
18.42
Dividend yield
0.02%
Average volume
362.72K
Volume
264.98K
Open price
$73.31
High today
$74.00
Low today
$72.42
52 Week high
$97.00
52 Week low
$69.58

ANI Pharmaceuticals (ANIP) at a glance

As of Oct 20, 2026, ANI Pharmaceuticals (ANIP) shares are priced at $72.67, giving the company a market cap of 1.67B, a price-to-earnings ratio of 18.42 and a dividend yield of 0.02%.

Today the stock has traded between $72.42 and $74.00. The current price is 0.3% above the day's low and 1.8% below its high.

Volume so far is 264.98K shares, below the average of 362.72K shares a day.

Over the past year ANI Pharmaceuticals has ranged from $69.58 to $97.00, and now sits 11% of the way up that range.

ANI Pharmaceuticals met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $2.21 per share against an estimate of $2.09.

The average analyst price target is $106.72, 46.9% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 4 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 11 analystsAvg $106.72
Low
$85.85
Now
$72.67
High
$127.05

ANIP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 20.7% on average.

  1. Q3 FY24: reported $1.34 per share against an estimate of $1.11
  2. Q4 FY24: reported $1.63 per share against an estimate of $1.46
  3. Q1 FY25: reported $1.70 per share against an estimate of $1.41
  4. Q2 FY25: reported $1.80 per share against an estimate of $1.45
  5. Q3 FY25: reported $2.04 per share against an estimate of $1.79
  6. Q4 FY25: reported $2.33 per share against an estimate of $2.04
  7. Q1 FY26: reported $2.05 per share against an estimate of $1.33
  8. Q2 FY26: reported $2.21 per share against an estimate of $2.09

ANIP news

  • Press releaseGlobe Newswire

    ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

  • Press releaseGlobe Newswire

    ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting

  • Press releaseGlobe Newswire

    ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

  • Press releaseGlobe Newswire

    ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

  • Press releaseGlobe Newswire

    ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

  • Press releaseGlobe Newswire

    ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

  • Stjepan Kalinic

    Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

  • Press releaseGlobe Newswire

    ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

Similar companies

Companies in the same industry as ANI Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.